• Hi-Tech Pharmacal Co., Inc.
    Cataract/Anterior Segment

    The U.S. FDA has approved an abbreviated new drug application for a generic version of once-daily ophthalmic solution, 0.09%, according to a press release from Hi-Tech Pharmacal.

    Hi-Tech Pharmacal, which makes the generic version of ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%, expects to immediately launch the generic drug.

    Bromfenac is used for reducing inflammation and ocular pain after cataract surgery.

    Additionally, the specialty pharmaceutical company expects to close this quarter on its acquisition by Akorn, Inc., for $640 million or $43.50 per share.